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Abstract As part of its Medical Technologies Evaluation
Programme, the National Institute of Health and Clinical
Excellence (NICE) invited the manufacturer, Covidien, to
provide clinical and economic evidence for the evaluation
of the PipelineTM embolization device (PED) for the
treatment of complex intracranial aneurysms. Cedar; a
consortium between Cardiff and Vale University Health
Board and Cardiff University, was commissioned to act as
an External Assessment Centre (EAC) for NICE to inde-
pendently critique the manufacturers’ submissions. This
article gives an overview of the evidence provided, the
findings of the EAC and the final guidance published by
NICE.
The scope issued by NICE considered PED as the
intervention in a patient population with complex un-
ruptured intracranial aneurysms (IAs), specifically large/
giant, wide-necked and fusiform aneurysms. The com-
parator treatments identified were stent-assisted coiling,
parent vessel occlusion, neurosurgical techniques and
conservative management. The manufacturer claimed that
PED fulfils a currently unmet clinical need in the treat-
ment of large or giant, wide-necked or fusiform IAs.
Thirteen studies were identified by the manufacturer
as being relevant to the decision problem, with two of
these included for data extraction. The EAC identified
16 studies as relevant, three of which had been pub-
lished after the manufacturer’s search. Data extraction
was carried out on these studies as, although many were
low level research comprising of case reports and case
series, they provided useful, pertinent safety and out-
come data.
No relevant economic studies of the device were iden-
tified; therefore, a new economic model was designed by
the manufacturer. The base-case scenario provided recog-
nized the costs of PED to be higher than the costs for
endovascular parent vessel occlusion, neurosurgical parent
vessel occlusion, neurosurgical clipping and conservative
management. However, PED was found to be cost saving
compared with stent-assisted coiling, with a saving of
£13,110 per patient.
Analysis of the clinical data suggested that treatment
with PED has high rates of clinical success with high rates
of aneurysm occlusion and acceptable adverse events for
the patient population. Economic evidence suggested that
the costs in the base-case for PED may have been under-
estimated, meaning that PED would only become cost
saving in patients who would otherwise require treatment
with 32 coils or more. NICE Medical Technologies Guid-
ance MTG10, issued in May 2012, recommends the
adoption of PED in selected patients within the UK
National Health Service (NHS).
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Key Points for Decision Makers
• The clinical evidence comparing the efficacy of the
PipelineTM embolization device (PED) with other
interventions is very limited, but current data sug-
gests high rates of successful device placement and
occlusion.
• The ‘value’ of PED is case dependent. Evidence
supports its use in patients with complex large or
giant intracranial aneurysms that are not suitable for
surgery and are being considered for stenting, when
the number of PEDs does not exceed two and when
32 or more coils and one stent would be needed
during stent-assisted coiling.
• A small number of patients have intracranial aneu-
rysms that are unsuitable for conventional types of
treatment and are at high risk of aneurysm rupture.
For these patients, the PED offers the only possible
means of treatment.
1 Introduction
The Medical Technologies Evaluation Programme (MTEP)
has been established since 2009 when it was set up by the
National Institute of Health and Clinical Excellence
(NICE) to facilitate the adoption of efficient and value-for-
money medical devices and diagnostics more rapidly and
consistently in the UK National Health Service (NHS).
Devices that meet the eligibility criteria and fall within the
remit of the programme can be notified to NICE by a
manufacturer. Following notification, MTEP selects devi-
ces that are likely to offer significant benefit to patients or
the NHS at the same or reduced cost when compared with
current practice for assessment under their programme.
Once selected, the device manufacturer is asked to provide
NICE with clinical and cost evidence submissions that
meet a pre-defined scope. This evidence is independently
critiqued, alongside the manufacturer’s submission, by an
External Assessment Centre (EAC) and a report is pro-
duced. This report is presented to the NICE Medical
Technologies Advisory Committee (MTAC), which is
made up of 25 independent specialists. The committee uses
the report in combination with other resources to produce
guidance on the technology under evaluation. This article
presents a summary of the EAC report for the PipelineTM
embolisation device for the treatment of complex intra-
cranial aneurysms, and the development of the NICE
guidance. It is one of a series of NICE Medical Technology
Guidance summaries being published in Applied Health
Economics and Health Policy [1, 2].
2 The Decision Problem
2.1 Disease Overview—Intracranial Aneurysms
Intracranial aneurysms (IAs), also known as cerebral or
brain aneurysms, occur when a weakness develops in the
wall of an artery supplying blood to the brain. This
weakness allows the vessel to balloon or bulge and the
resultant sac fills with blood to form an aneurysm. It has
been estimated that approximately 2.8% of the population
have a brain IA, with a higher prevalence in women at a
ratio of 1.57 [3].
Types of aneurysms include saccular (or berry) and
fusiform, with saccular aneurysms being spherical in shape
with a distinctive neck while fusiform aneurysms have no
distinct neck (Fig. 1). Small, unruptured aneurysms are
usually asymptomatic; however, larger aneurysms can
result in ‘mass effect’ due to compression of adjacent
nerves and tissues causing features which can include
headache, double vision, slurred speech and seizures.
Untreated aneurysms are at significant risk of rupture
leading to subarachnoid haemorrhage (SAH), which carries
a high rate of morbidity and mortality. Thirty to forty
percent of SAH patients die within 1 month and 10–20 %
of survivors have long-term dependence due to brain
damage [4]. Data suggest that larger aneurysms carry a
higher risk of rupture than smaller ones. The International
Fig. 1 Representation of saccular (a) and fusiform (b) aneurysms
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Study of Unruptured Intracranial Aneurysms (ISIUA)
Investigators [5] found 5-year rupture rates of 2.6 % for
aneurysms of 7–12 mm, 14.5 % for those 13–24 mm and
40 % rupture rates for aneurysms of 25 mm or greater.
2.2 Current Treatment Options
Several neurosurgical treatment options are available for
patients with IAs, including clipping, wrapping and
bypass procedures. Surgical clipping was developed in the
1930s and was the standard therapy for IAs for many
years; it continues to be used regularly due to its long-
term efficacy. The technique involves a clip being placed
across the neck of the aneurysm, excluding it from the
circulation. In 1991, an endovascular technique using
coils was introduced as an alternative therapy and its use
has increased substantially, with coil embolization often
used as a first-choice treatment due to the lower risk of
morbidity and mortality [6]. Surgical clipping involves the
insertion of a microcatheter into an artery and up into the
targeted aneurysm. Platinum coils are fed into the aneu-
rysm, filling the sac and preventing or reducing blood
flow. Coiling is often used in conjunction with stents that
are positioned in the main artery to prevent the coils
migrating from the aneurysm.
Parent vessel occlusion (PVO) is an option for treatment
of IAs where sufficient collateral circulation exists. In these
cases the parent artery is occluded surgically or using an
endovascular method (e.g., using balloons or coils),
effectively preventing blood flow in the artery and thus the
aneurysm. PVO is not suitable for all patients since it
requires an adequate alternative circulation as without this,
occluding the artery will result in a stroke. PVO is usually
reserved for aneurysms that cannot be treated by other
techniques [7].
In some patients, the shape, size or location of an
aneurysm prohibits effective treatment using existing
therapies, while for other patients previous attempts at
treatment have failed. In these patients conservative man-
agement may be the only option available. This remains a
high-risk option for many patients due to the poor long-
term prognosis of large, complex aneurysms.
NICE has published several guidance documents to
assist with the treatment of IAs; however, these do not
specifically address the patient population defined within
the scope of this review.
2.3 PipelineTM Embolization Device
Manufactured by Covidien in the US, the PipelineTM
embolization device, or PED, is a stent-like structure made
of braided cobalt chromium and platinum tungsten. It is
delivered via a microcatheter and is designed to be placed
across the neck of an IA, thereby disrupting the flow of
blood within the aneurysm. This reduced flow increases the
blood viscosity, eventually leading to clotting of the blood
within the aneurysm itself. Furthermore, the PED forms a
scaffold over which endothelial cells can grow, eventually
incorporating the PED into the wall of the parent artery.
This forms a biological seal and the aneurysm becomes
excluded from the circulation completely. Over time the
clotted aneurysm may reduce in size, and symptoms of
mass effect may also diminish [8]. PED’s are available in
various lengths between 10 mm and 35 mm and can
expand between 2.5 mm and 5 mm in diameter. They can
be deployed one within another or telescoped to increase
the overall length or surface coverage over the area being
treated. Due to their flexible nature they can be used in
vessels with tortuous anatomy while their configuration
allows continued circulation in perforators and side
branches.
2.4 National Institute of Health and Clinical
Excellence (NICE) Scope
The scope of the decision problem outlined by NICE
identified the PED as the intervention to be studied. The
patient population was defined as ‘‘Patients with complex
intracranial aneurysms, specifically large/giant, wide
necked and fusiform aneurysms’’. Discussions during the
preliminary stages of the assessment clarified that ruptured
aneurysms should be excluded from the scope. Several
comparators were identified for consideration: stent-assis-
ted coiling (SAC); parent vessel occlusion; neurosurgical
techniques and conservative management. Ten outcome
measures were specified for consideration: successful
device deployment; successful occlusion of the aneurysm;
size of collective aneurysm-thrombus mass; resolution of
symptoms; resource use outcomes; stroke; delayed parent
vessel occlusion; subarachnoid haemorrhage/other major
bleeding events requiring active treatment; neurovascular
death; and device-related adverse events. The scope also
requested three separate cost analyses:
Analysis 1 Population: patients with complex IAs for
whom SAC is considered feasible (de novo or repeat
treatment). Intervention: PED. Comparator: percutaneous
interventional techniques including SAC and parent vessel
occlusion.
Analysis 2 Population: Patients with complex IAs for
whom SAC is not considered feasible (de novo or repeat
treatment). Intervention: PED. Comparator: neurosurgical
techniques (including bypass).
Analysis 3 Population: Patients with complex IAs for
whom SAC and neurosurgical techniques are not consid-
ered feasible (de novo or repeat treatment). Intervention:
PED. Comparator: conservative treatment.
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3 External Assessment Centre (EAC) Review
Cedar, a consortium between Cardiff and Vale University
Health Board and Cardiff University, was commissioned
by NICE to act as the EAC to independently evaluate the
PED. The role of the EAC is to review and critique the
manufacturers’ submissions and produce a structured
report on their findings. Nominated expert advisers are also
available to the EAC to provide clinical advice if required
during the process.
As per NICE requirements, Covidien made a submission
based on the scope of the decision problem. The first part is
a clinical submission comprising an overview of the dis-
ease and current treatment provision with a review of the
available clinical literature relating to PED and its com-
parator technologies. This is followed by an economic
submission comprising a search strategy and relevant
economic evidence and a de novo economic model
accompanied by a detailed description.
3.1 Clinical Effectiveness Evidence
The manufacturer used Hospital Episode Statistic (HES)
data from 2009–2010, which identified 2,191 patients in
England and Wales with a primary diagnosis of unruptured
IA. Using data from the ISUIA study [5] to estimate the
prevalence of large and giant aneurysms, Covidien calcu-
lated the number of patients with unruptured aneurysms
eligible for treatment with PED in England and Wales to be
between 460 and 580 annually.
Covidien identified 13 studies as being appropriate to
the decision problem, with two multicentre, prospective,
single-arm feasibility studies forming the main evidence
base. PITA (the PipelineTM Embolization Device for the
Intracranial Treatment of Aneurysms trial) [9] was a fea-
sibility study that monitored 31 patients (and 31 aneu-
rysms) over 180 days. The study endpoints were successful
device placement and the incidence of death or ipsilateral
stroke at 30 days in a patient population with unruptured
aneurysms that were wide necked (C4 mm), had unfa-
vourable dome/neck ratios (\2) or had failed previous
therapy. In thirty cases, device placement was successful
while in the remaining patient, diminished blood flow in
the parent artery required corrective angioplasty that led to
rupture of the artery and subsequent artery ligature. Two
patients experienced periprocedural strokes. No other
patients showed signs of neurological deterioration and
there were no deaths. Aneurysm occlusion rates were high
with a rate of 93.3 % observed in the thirty patients who
received angiographic follow up at 180 days.
The PipelineTM for Uncoilable or Failed Aneurysms
Study or PUFS [8] is an ongoing unpublished study fol-
lowing 108 patients with 110 aneurysms, which is due to
complete in June 2014. These aneurysms were both wide
necked (C4 mm) and either large (10–25 mm) or giant
([25 mm), with the primary effectiveness endpoint being
complete occlusion of the target aneurysm at 180 days in
the absence of major stenosis. Device placement was
successful in 99 % of patients with rates of complete
occlusion (without major stenosis when using PED alone)
of 73.6 %. Ipsilateral stroke or death by 180 days after the
procedure was the stated primary safety end point and
occurred in six patients (5.6 %). The data from this trial are
available from the Executive Device Summary for PED,
published online by the US Food and Drug Administration
(FDA) [8].
The remaining eleven identified studies [10–20] were
excluded from qualitative synthesis by the manufacturer as
they were not felt to be sufficiently robust to be included
due to their design. Several of these are case reports or case
series involving a relatively small number of patients. A
degree of patient duplication was also given as a reason for
study exclusion.
3.1.1 Critique of Clinical Effectiveness Evidence
EAC discussions with the clinical experts suggested the
number of patients estimated by Covidien to be suitable for
treatment with PED was excessively high. As NICE
guidance is targeted at the NHS in England, data on Welsh
patients were excluded, and repeat admissions on HES
were identified for removal. This left an estimated 333–420
patients in England eligible annually.
The manufacturer provided a clear overview of the
condition, and the advantages and disadvantages of current
treatment options were well described and their compari-
son to PED clearly illustrated. A well structured literature
search was carried out and most of the relevant studies
identified; however, the manufacturer excluded most of
these from the data extraction process. The two studies that
formed the main evidence base were highly relevant to the
decision problem and were discussed in detail throughout
the manufacturer’s submission. Of the eleven additional
studies that were identified by Covidien, one of these [16]
presented data on ruptured aneurysms that were identified
as being outside the scope of the decision problem and it
was therefore excluded from data extraction by the EAC.
The manufacturer excluded the remaining ten studies from
the data extraction process due to concerns regarding study
quality, but the EAC felt that despite their limitations, these
studies provided valuable data pertinent to the scope of the
submission.
Using an adapted literature search, the EAC identified
an additional case report not found by the manufacturer
[21]. Three further studies [22–24] were identified that
were published after the date of the manufacturer’s
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literature search. This led to the EAC including a total of
16 studies comprising one unpublished trial, one journal
letter, four conference abstracts and ten published manu-
scripts. The EAC considered that although there was a
degree of patient duplication, it was important to carry out
data extraction on all relevant studies to ensure pertinent
evidence was not omitted. A total of approximately 379
patients were described in the included literature; one study
[18] described the treatment of 42 aneurysms but did not
specify the number of patients. As previously noted, the
total number of patients treated is fewer than the sum from
the literature included due to duplication across studies.
As well as concerns regarding the design of some of the
studies reported in the literature, there were other limita-
tions in the clinical evidence available for PED. These
included an absence of control groups in any of the studies;
lack of clarity in reporting inclusion and exclusion criteria;
the duplication of patients between studies; and lack of
detail in the conference abstracts. As PED is a relatively
new device there is a shortage of long-term follow-up data.
However, the nature of the disease, lack of clinical equi-
poise and small patient numbers makes comparative stud-
ies inappropriate in the population being studied.
The EAC considered adverse event data from the
manufacturer’s own sources and from the MAUDE
(Manufacturer and User Facility Device Experience)
database was pertinent to the decision problem and should
be included. Data from MAUDE was accessed, and Co-
vidien provided adverse event data on request, with this
information being incorporated into the EAC report.
Despite being primarily low-level studies, the clinical
evidence provided a large amount of data that was highly
relevant to the scope of the decision problem, with data
available on nine of the ten specified outcome measures.
The studies showed a high rate of clinical success with few
difficulties in device deployment and only three cases of
delayed parent vessel occlusion reported. Aneurysm
occlusion rates were well documented, being reported in
twelve studies with seven studies reporting 100 % occlu-
sion [10, 11, 14, 17, 19, 21, 24]: the lowest rate reported
was 69 % [23]. No data was available on resource use
outcomes.
3.2 Cost Evidence
The manufacturer provided details of the search strategy
used to identify economic studies relevant to the scope: no
relevant papers were identified. One unpublished document
was provided by Covidien, comprising a simple cost cal-
culation produced by the previous manufacturer; however,
this was felt to be inadequate for the economic evaluation.
The manufacturer produced a de novo model consisting of
a short-term ‘decision tree’ with an additional long-term
Markov element reflecting a time horizon of 10 years with
a 6-month cycle length. The short-term data separated
surviving patients into three occlusion categories: complete
occlusion, residual neck and residual aneurysm. There
were three health states used in the long-term model, these
were i) no-complications; ii) re-treatment; iii) rupture
resulting in survival or death: patients can also die from all
causes at any time in the model. The model used an NHS
and personal social service perspective with discounting
for costs and QALYs (quality-adjusted life-years) applied
at a rate of 3.5 % as per NICE guidance. However, as
MTEP does not look at the cost effectiveness of a device,
the QALY data were not considered by the committee in
their decision.
The steps of the model were:
1. Treatment (followed by survival/death)
2. Initial outcome for surviving patients (split into three
groups: complete occlusion; residual neck; residual
aneurysm)
3. Prediction of ongoing outcomes (defined as no com-
plication; retreatment; rupture)
4. Results (this includes costs and incremental costs)
Additional options included adverse events defined as
SAH and stroke.
Lack of data prevented sensitivity analysis on the
structural assumptions within the model, but an extensive
one-way sensitivity analysis was carried out to measure the
impact of numerous inputs within the model. This identi-
fied the most critical areas and highlighted that the model
was particularly responsive to the cost of consumables used
both for PED and its comparators. The base-case scenario
illustrated total procedure costs over the 10-year time
horizon for PED as £24,341. This is compared with
£16,893 for endovascular PVO, £11,654 for neurosurgical
PVO, £11,658 for neurosurgical clipping and £10,352 for
conservative management. Only SAC was shown to be
more costly than PED at £37,451, showing PED at a cost
saving of £13,110 per treatment, making PED dominant.
This is based on list prices of £10,171.00 for PED and
£526.04 for coils. Covidien estimated the number of PEDs
required to be 1.46 based on their own data on file, while
the inputs used for the number of coils was based on an
opinion in an editorial [25] that estimated a requirement of
40 coils for SAC.
3.2.1 Critique of Cost Evidence
The EAC felt the search strategy used to identify relevant
economic studies was appropriate in regard to both search
terms and databases utilized and did not repeat the search.
The search and selection criteria used by the manufacturer
to identify data sources for cost and clinical outcomes used
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in the cost model were not specified, therefore the EAC
were unable to quality check the selection used or to
confirm that these were the most appropriate sources. This
is also true of the sources used to justify the assumptions
made throughout the model, and while those identified by
the manufacturer were clearly described and referenced, it
is unclear how they were chosen. The structure of the
model itself was well executed, with data sources clearly
labelled. However, in some instances secondary references
were used, and some inputs relied on extrapolated data,
which in several cases were combined from a number of
studies including some not directly relevant to the decision
problem. This led to uncertainties at each stage in the
model.
Adverse events were inadequately explored in the sub-
mission, and the model only included subarachnoid
haemorrhage and stroke, with some types of stroke being
excluded for the comparator treatments. For the compara-
tor, many of the complications listed as adverse events also
resulted in death within 31 days. The structure of the model
meant that some of this data was double counted when the
option for adverse events was selected as they also con-
tributed to the perioperative mortality figures used in the
model at an earlier stage.
As identified by the manufacturer following sensitivity
analysis, the cost of consumables was a key driver, with
the model being particularly responsive to the cost and
number of PEDs and coils used. Covidien quoted list
prices for PED of £10,171 and coils at £526.04, and used
data on file to estimate the number of PEDs required at
1.46. The number of coils required was estimated at 40,
making PED dominant compared with SAC. The EAC
determined that the numbers estimated for coils and PED
may not be appropriate and following consultation with
the expert advisers estimated that the average number of
coils required may be lower at approximately 25 while
data from the studies identified in the clinical review
suggested the average number of PEDs used would be
higher than in the model at an estimated 2.4 devices. This
would significantly increase the cost of PED in compari-
son with SAC, meaning that PED became the more costly
option. Lack of data means that these inputs remain
uncertain; however, doubt particularly surrounds the
appropriate number of coils. The uncertainty regarding the
number of PEDs and coils required to treat aneurysms in
the target population is a critical parameter that poten-
tially has a significant impact on the outcome of the
model. The EAC determined that, for 2.4 PEDs, the
model shows PED to be cost saving when the number of
coils required is equal to or greater than 36.
The scope issued by NICE requested three cost analyses
to be performed; the model provided deviated in respect to
cost analysis in several areas:
Analysis 1 This was generally implemented as reques-
ted, however the scope indicated that SAC is a feasible
retreatment in the population analysed, and while the
model does apply this correctly, the manufacturer’s report
stated that retreatment would be via neurosurgical clipping.
Analysis 2 Although included in the scope, it is unclear
if the manufacturer included bypass along with other
neurosurgical techniques in the model. Retreatment after
neurosurgical clipping is costed as SAC in the model
although the scope indicates that the population should
comprise patients for whom SAC is not feasible.
Analysis 3 In the scope, the population comprised
patients treated with conservative management for whom
SAC and neurosurgical techniques were not feasible.
However, the model incorporated retreatment costs using
SAC in this group; removing this element reduces the cost
of conservative management further.
3.3 Conclusion of the EAC
As noted by the manufacturer, there are considerations
regarding the use of low-level evidence such as case
reports and case series due to the risk of selection and
reporting bias. However, in the absence of more robust
studies such as randomized controlled trials as is often the
case for novel treatments, particularly for those such as
PED for whom comparator studies are not appropriate, they
can provide valuable information on initial treatment effi-
cacy and adverse events. Despite the concerns regarding
study quality and patient duplication, the results of the
studies identified are encouraging with the outcome mea-
sures addressed within the scope of the decision problem
showing promising results. Rates of successful device
placement and aneurysm occlusion are high and adverse
events such as stroke, neurovascular death and delayed
parent vessel occlusion were relatively low for this patient
population. PED offers the benefit of long-term vessel
patency and resolution of symptoms in some patients,
which would not be afforded via many treatment
alternatives.
The economic analysis for PED relies on the economic
model, the accuracy of which is dependent on the inputs,
and many of these are surrounded by a degree of uncer-
tainty. The key drivers in analysis 1 of the scope are the
number of PEDs and coils required, and the data provided
to support these estimates is weak. Under the scope of the
decision problem as identified by the manufacturer, the
only treatment option for the patient population identified
against which PED may be potentially cost saving is SAC.
Here the most economic option will vary on a case-by-case
basis requiring clinical assessment to estimate the potential
number of coils or PEDs required in an individual patient;
however, the EAC feels that the number of coils required
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would be larger than estimated by the manufacturer before
PED becomes dominant. There remains a group of patients
who have failed previous treatments or cannot be treated
via conventional methods: for these patients no other
treatment options exist.
4 NICE Guidance
In line with the MTEP process, the Committee met to
develop draft recommendations following which a medical
technology consultation document was produced. NICE
accepted comments on these draft recommendations as
well as notification of inaccuracies and additional infor-
mation. Following a consultation period, comments were
collated and presented to the committee for discussion.
4.1 Draft Recommendations
The MTAC Committee met in October 2011 and, follow-
ing review of the manufacturer’s submissions and the EAC
report [26] together with evidence from expert advisers, the
following provisional recommendations were made:
1. ‘‘The case for adopting the Pipeline embolisation
device in the NHS is supported by the current evidence
when it is used in patients with giant or complex
intracranial aneurysms that are unsuitable for surgery,
which are being considered for stenting and where
large numbers of coils are needed during stent-assisted
coiling.
2. The Pipeline embolisation device is estimated to be
cost saving when compared with stent-assisted coiling,
in patients with giant or complex intracranial aneu-
rysms when the number of Pipeline embolisation
devices inserted does not exceed two and when
treatment would otherwise require the use of 29 or
more coils combined with one stent for stent-assisted
coiling. If two Pipeline embolisation devices are used
the total procedure cost is estimated as £30,354
compared with £30,775 for the use of 29 coils for
stent-assisted coiling (a saving of £421 using the
Pipeline embolisation device).
3. Clinicians should submit details of all patients being
treated with the Pipeline embolisation device to the
UK Neurointerventional Radiology Group audit data-
base, to increase the evidence base and guide future
use of this technology.’’
The Committee noted that for some patients with
aneurysms unsuitable for treatment with existing therapy
options PED may be the only treatment available. However
these patients are beyond the scope of this
recommendation.
4.2 Consultation Response
There were numerous comments sent to NICE during the
PED public consultation period. These raised issues includ-
ing the differences in practice between the UK and the US,
where many of the published studies were carried out. Some
of these suggested changes were felt to be outside of the scope
of the guidance and remit of the programme; however, other
comments were considered by the Committee for inclusion
while some comments led to automatic changes being made
to ensure that data reported were clear and accurate.
During the consultation period, the expert advisers
suggested that five inputs in the economic model could be
addressed more suitably. One of these changes was felt to
be inappropriate as the manufacturer’s original inputs were
correctly referenced and valid. However, it was determined
that four of the suggested changes would better reflect UK
practice. The EAC subsequently produced an additional
report to explain these changes and their impacts on the
cost model; this identified the following changes.
• The model assumed that while treatment with PED
requires one Marksman microcatheter at a list price of
£1030.00, two would be needed for treatment via SAC at a
total cost of £2060.00. The expert advisers confirmed that
while two microcatheters are required for SAC, standard
practice in the UK involves the use of cheaper alternatives
to the Marksman, with the EAC calculating an average
cost for microcatheters of £460.50 each, reducing the total
cost of these to £921.00.
• Balloon use was estimated to occur in 50 % of SAC
procedures but no PED procedures in the model. While
it was not possible to determine an absolute rate of use,
it was felt by the expert advisers that their use is
relatively uncommon for both methods of treatment and
was therefore removed from the cost model.
• An additional cost for endovascular equipment was
included in the model but only for retreatment for SAC
and not de novo treatment or for any other comparator or
PED. Removal of this reduces the cost in favour of SAC.
• Drug resource use was calculated using data from non-
comparable studies due to the lack of comparator
studies. The study selection criteria were not specified,
but the data used was not inappropriate. However, two
minor calculation errors were identified in the number
of days of drug therapy making very small reductions in
the cost of both PED and SAC.
4.3 Final Guidance
The final Medical Technology Guidance document for
PED for the treatment of complex IAs was published by
NICE on 30 May 2012 as MTG10 [27]. Due to the impact
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of the changes made following suggestions from the Expert
Advisers, one of the recommendations was updated as
detailed below to more accurately reflect the number of
coils required before PED became cost saving:
‘‘The Pipeline embolisation device is estimated to be
cost saving when compared with stent-assisted coil-
ing, in patients with complex giant or large intra-
cranial aneurysms when the number of Pipeline
embolisation devices inserted does not exceed two,
and when treatment would otherwise require the use
of 32 or more coils combined with one stent for stent-
assisted coiling. If two Pipeline embolisation devices
are used the total procedure cost is estimated as
£30,346 compared with £30,838 for the use of 32
coils for stent assisted coiling (a saving of £492 using
the Pipeline embolisation device).’’
5 Challenges
There were several challenges and learning points identi-
fied throughout the evaluation process. These mainly arose
from two primary issues and are potentially factors which
may impact other emerging medical technologies.
1) Patient numbers The patient population suitable for
treatment with PED is very small and difficult to
quantify accurately, particularly regarding the sub-set
of patients for whom no other treatment options exist.
The small patient population means that it is not
feasible to carry out randomized controlled trials or
comparator studies, particularly as many of the
patients suitable for treatment will have failed previ-
ous treatment or will not be suitable for alternative
procedures. This means that the evidence for this type
of device will rely on less robust data such as case
series and case reports. Complexities in identifying the
number of eligible patients also makes it difficult to
calculate the overall cost impact of adopting the
technology.
2) Sources of data Most of the study data for patients treated
with PED were based on patients treated in the US; no
study data were available from the UK. Differences in
clinical practice can result in misleading data being used
to evaluate factors such as cost and efficacy. For
example, patient selection, surgical techniques and
treatment options may differ between countries, thus
affecting the number of patients treated and potentially
distorting extrapolated outcome data. The absence of
fully researched data on the comparator technologies
may also lead to inaccuracies in the assessment and
comparison of the available evidence.
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